Compare JKS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JKS | NVCR |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2010 | 2015 |
| Metric | JKS | NVCR |
|---|---|---|
| Price | $21.35 | $12.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $25.25 | ★ $28.08 |
| AVG Volume (30 Days) | 463.3K | ★ 1.0M |
| Earning Date | 04-16-2026 | 04-30-2026 |
| Dividend Yield | ★ 5.37% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | $37.42 | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $15.55 | $9.82 |
| 52 Week High | $31.88 | $20.05 |
| Indicator | JKS | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 59.73 |
| Support Level | N/A | $10.72 |
| Resistance Level | $26.33 | $13.59 |
| Average True Range (ATR) | 1.13 | 0.55 |
| MACD | -0.17 | 0.20 |
| Stochastic Oscillator | 17.01 | 95.30 |
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.